Skip to main content
Premium Trial:

Request an Annual Quote

EpiVax Wins $600K SBIR Grant to Develop Vaccine Against H. Pylori

NEW YORK, May 5 (GenomeWeb News) - The US National Institutes of Health awarded EpiVax a $600,000 Phase I Small Business Innovation Research grant to develop a vaccine to Helicobacter pylorus, a common cause of peptic ulcers, the company said last week.

 

The grant will is the third such award the company has received in the past six months, bringing to $2.5 million the total grant funds received. The other two grants include a $1 million SBIR award to develop a smallpox vaccine and a $859,773 biodefense grant to develop a vaccine for Tularemia.

 

EpiVax is also developing vaccines to HIV and tuberculosis, the company said.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.